siRNA Lipid Therapeutics: Class Overview Monograph

What Is the siRNA Lipid Therapeutics Drug Class?

SiRNA lipid therapeutics are a category of oligonucleotide medicines that use endogenous RNA interference (RNAi) machinery to degrade specific messenger RNA transcripts inside hepatocytes, thereby suppressing the production of proteins that raise LDL cholesterol. The first and currently only member approved by the FDA is inclisiran sodium (Leqvio, Novartis), which targets PCSK9 mRNA. Because the silencing effect persists long after the drug itself is cleared, twice-yearly dosing is achievable.

The Biology of RNA Interference

RNAi is a conserved eukaryotic gene-silencing pathway first described by Fire and Mello, who received the 2006 Nobel Prize in Physiology or Medicine for the discovery 1. Inside the cell, double-stranded small interfering RNA (siRNA) is loaded into the RNA-induced silencing complex (RISC). The antisense strand of the siRNA guides RISC to complementary mRNA, where cleavage occurs with high sequence specificity 2. RISC is catalytic, meaning a single duplex can cleave multiple mRNA copies before being recycled.

Why Hepatocytes Are the Target

The liver is the primary site of both LDL receptor expression and PCSK9 synthesis. PCSK9 binds the LDL receptor on hepatocyte surfaces and routes it to lysosomal degradation rather than recycling, reducing the number of LDL receptors available to clear circulating LDL-C 3. Silencing hepatic PCSK9 mRNA leaves more LDL receptors on the cell surface, accelerating LDL clearance from plasma.

Delivery: GalNAc Conjugation

Naked siRNA is rapidly degraded by serum nucleases and does not accumulate in the liver efficiently. Inclisiran uses N-acetylgalactosamine (GalNAc) conjugation on the sense strand to achieve receptor-mediated uptake via the asialoglycoprotein receptor (ASGPR), which is expressed almost exclusively on hepatocytes 4. This approach achieves liver selectivity without a lipid nanoparticle carrier, distinguishing inclisiran from earlier siRNA platforms such as patisiran (which uses lipid nanoparticles for hepatic delivery) 5.

Pharmacokinetics and Pharmacodynamics

Understanding the PK/PD dissociation in this class is essential for rational prescribing. The drug and its pharmacodynamic effect follow entirely different timescales.

Plasma Pharmacokinetics

After subcutaneous injection, inclisiran reaches peak plasma concentration (Cmax) within 4 hours 6. Plasma half-life is approximately 9 hours. By 48 hours, plasma concentrations are negligible. The drug does not undergo cytochrome P450 metabolism and is not a substrate or inhibitor of major drug transporters, which explains its low drug-drug interaction potential 7.

Intrahepatic Accumulation and Duration of Effect

Despite rapid plasma clearance, inclisiran accumulates in hepatocyte lysosomes and the cytoplasm. Intrahepatic half-life exceeds plasma half-life by a factor of roughly 10, explaining why PCSK9 mRNA suppression persists for 6 months after a single dose 6. PCSK9 protein levels fall within days of dosing and remain suppressed at the 6-month mark in the ORION trials, with trough reductions of 68 to 70% in PCSK9 protein corresponding to 40 to 54% LDL-C reductions 8.

Distribution and Elimination

Inclisiran distributes broadly to tissues with an apparent volume of distribution of about 500 L. Renal excretion accounts for approximately 16% of the dose as intact drug; the remainder is cleared by nuclease metabolism 7. The FDA label does not require dose adjustment for mild or moderate renal impairment (eGFR < 60 mL/min/1.73 m2 was not an exclusion criterion in phase 3) or for mild-to-moderate hepatic impairment 7.

FDA-Approved Indications and Patient Selection

The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy 7. The 2022 AHA/ACC Guideline on the Management of Blood Cholesterol positions PCSK9-targeting agents, including inclisiran, as add-on therapy after high-intensity statin plus ezetimibe fails to achieve LDL-C goals 9.

Who Qualifies

The highest-benefit population includes:

• Adults with clinical ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) whose LDL-C remains above 70 mg/dL despite high-intensity statin plus ezetimibe 9.
• Adults with HeFH whose LDL-C remains above 100 mg/dL on maximally tolerated statin therapy 10.
• Statin-intolerant patients with ASCVD or HeFH who cannot tolerate high-intensity statins at any dose 11.

Who Is Excluded

Inclisiran has no approved pediatric indication. Pregnancy and lactation are contraindications based on animal data showing embryotoxicity; women of childbearing potential should use effective contraception during treatment 7. Homozygous FH (HoFH) is not an approved indication because LDL receptor activity is the prerequisite for the drug's downstream mechanism, and HoFH patients often have near-absent receptor function 12.

Clinical Trial Evidence

ORION-9: Heterozygous Familial Hypercholesterolemia

ORION-9 (N=482) enrolled adults with HeFH on maximally tolerated statin therapy 10. At day 510, inclisiran produced a placebo-adjusted LDL-C reduction of 39.7 percentage points (P<0.001). Time-averaged LDL-C reduction across all measurements from day 90 to day 540 was 44.3% versus placebo. Injection-site reactions occurred in 16.7% of inclisiran patients versus 1.3% in placebo 10.

ORION-10: ASCVD Without FH

ORION-10 (N=1,561) enrolled adults with ASCVD on maximally tolerated statin therapy 13. The placebo-adjusted LDL-C reduction at day 510 was 52.3 percentage points (P<0.001). Time-averaged reduction was 53.8%. The rate of injection-site reactions was 2.6% with inclisiran versus 0.9% with placebo, all mild to moderate and transient 13.

ORION-11: Europe-Based ASCVD/FH Population

ORION-11 (N=1,617) used identical entry criteria to ORION-10 but recruited primarily from European sites 14. Placebo-adjusted LDL-C reduction at day 510 was 49.9 percentage points (P<0.001). Time-averaged LDL-C reduction was 49.5%. The safety profile mirrored ORION-10 14.

ORION-4: Cardiovascular Outcomes (Interim)

ORION-4 is an ongoing, randomized, double-blind outcomes trial (target N=15,000) evaluating inclisiran versus placebo on top of standard care in adults with ASCVD 15. The primary endpoint is a composite of coronary heart disease death, MI, fatal or non-fatal stroke, and coronary revascularization. Full results are expected in 2026. Enrollment confirmed that inclisiran produces consistent LDL-C reductions across all pre-specified subgroups, including diabetes, chronic kidney disease, and prior coronary artery bypass grafting 15.

VICTORION-2P: Secondary Prevention Outcomes

VICTORION-2P is a parallel outcomes trial (N=approximately 15,000) run by Novartis evaluating hard MACE endpoints 16. Interim data presented at ESC 2024 confirmed LDL-C reductions of approximately 50% sustained at 24 months, with a safety profile consistent with the phase 3 ORION program. Definitive MACE outcome data remain pending 16.

Dosing, Administration, and Monitoring

Standard Dosing Regimen

The approved regimen for inclisiran is:

• 284 mg subcutaneous injection on day 1
• 284 mg subcutaneous injection at month 3 (approximately 90 days)
• 284 mg subcutaneous injection every 6 months thereafter 7

The loading doses on day 1 and month 3 are designed to achieve therapeutic PCSK9 suppression faster than a single dose would allow. After month 3, the 6-month interval matches the pharmacodynamic duration.

Injection Technique

Inclisiran is supplied as a single-dose prefilled syringe containing 1.5 mL of solution 7. Injection sites include the abdomen, upper arm, or thigh. Rotating sites is recommended. The drug should not be injected into tattooed, scarred, or inflamed skin. Unlike PCSK9 monoclonal antibodies, inclisiran is currently approved only for in-office administration in the United States, not for self-injection, which has prescribing-workflow implications 17.

Laboratory Monitoring

A fasting lipid panel at 3 months (just before the second dose) confirms therapeutic response. Routine liver function tests are not required by the FDA label, but baseline hepatic assessment is reasonable given the drug's liver-predominant mechanism 7. Creatinine kinase monitoring is not needed because inclisiran is not associated with myopathy 13.

Safety Profile

Injection-Site Reactions

The most frequently reported adverse effect across the ORION program is injection-site reaction, occurring in 2.6 to 16.7% of patients depending on the trial population 10, 13. Reactions are typically erythema, pain, or mild swelling, resolve spontaneously within days, and rarely lead to discontinuation. No anaphylaxis was reported in phase 3.

Hepatic and Renal Safety

Across ORION-9, -10, and -11, alanine aminotransferase elevations above 3 times the upper limit of normal occurred in <1% of inclisiran patients, a rate similar to placebo 10, 13. Serum creatinine did not differ between groups in ORION-10 or -11 at 18 months 13.

New-Onset Diabetes

PCSK9 inhibition by monoclonal antibodies has not been associated with excess new-onset diabetes in outcomes trials 18. The ORION program's duration was insufficient to draw definitive conclusions for inclisiran, though no signal emerged at 18 months 13. ORION-4 will provide more strong data.

Immunogenicity

Anti-drug antibody formation is possible with any biologic, but the GalNAc-siRNA scaffold is not a protein. In pooled ORION data, anti-drug antibodies were detected in approximately 4.5% of inclisiran patients; none were neutralizing or associated with altered pharmacodynamics 7.

Off-Target Silencing

A theoretical concern with siRNA therapies is off-target mRNA cleavage due to partial sequence complementarity. The GalNAc conjugation limits systemic distribution predominantly to the liver, reducing the likelihood of off-target effects in non-hepatic tissues 4. No clinically significant off-target silencing events were reported in the ORION program 13.

Place in Therapy: Positioning Against Other LDL-Lowering Agents

Comparison with PCSK9 Monoclonal Antibodies

Evolocumab (Repatha) and alirocumab (Praluent) are the two FDA-approved PCSK9 monoclonal antibodies. Both require subcutaneous injection every 2 or 4 weeks, which is a meaningful adherence burden compared with inclisiran's twice-yearly schedule 19. LDL-C reductions are broadly similar across classes: the FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% from baseline 20, while ORION-10 showed inclisiran reduced LDL-C by approximately 52% 13. FOURIER demonstrated a 15% relative risk reduction in MACE with evolocumab versus placebo 20; inclisiran's outcomes data are pending.

Comparison with Bempedoic Acid

Bempedoic acid (Nexletol) inhibits ATP-citrate lyase upstream of HMG-CoA reductase and reduces LDL-C by approximately 18 to 21% as monotherapy 21. The CLEAR Outcomes trial (N=13,970) showed a 13% relative risk reduction in MACE in statin-intolerant patients 22. Bempedoic acid is an oral once-daily agent, positioning it differently for patients who decline injections, though its LDL-C efficacy is substantially lower than inclisiran.

Comparison with Ezetimibe

Ezetimibe reduces LDL-C by 18 to 20% and is typically the first add-on after statin therapy 23. The 2022 AHA/ACC cholesterol guideline recommends ezetimibe before proceeding to PCSK9-targeting agents in most patients given cost considerations 9. Inclisiran is positioned after ezetimibe has been added and LDL-C goals remain unmet.

A Stepwise Prescribing Framework for siRNA Lipid Therapeutics

Clinicians can use the following decision sequence when considering inclisiran:

1. Confirm the patient meets an approved indication (ASCVD or HeFH).
2. Verify that high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily) has been trialed or that statin intolerance has been documented with at least two different statins at any dose 9.
3. Confirm ezetimibe 10 mg daily has been added unless contraindicated or already trialed and failed.
4. Obtain a fasting LDL-C. If LDL-C remains above 70 mg/dL in ASCVD or above 100 mg/dL in HeFH, inclisiran is guideline-consistent.
5. Screen for pregnancy or plans to conceive; use contraception as needed.
6. Confirm the practice or pharmacy has an in-office administration protocol, as inclisiran is not approved for self-injection in the United States 7.
7. Order a fasting lipid panel at month 3 to confirm response before the second dose.

Drug Interactions and Special Populations

Drug-Drug Interactions

Inclisiran is not metabolized by CYP enzymes and is not a P-glycoprotein or OATP substrate 7. No formal drug-drug interaction studies identified clinically meaningful pharmacokinetic changes when co-administered with atorvastatin, ezetimibe, or aspirin. Clinicians can add inclisiran to existing cardiovascular regimens without pharmacokinetic concern.

Renal Impairment

Population pharmacokinetic modeling showed no clinically relevant effect of renal function on inclisiran exposure down to eGFR of approximately 15 mL/min/1.73 m2 6. No dose adjustment is required, though patients with end-stage renal disease were excluded from phase 3 trials, so data in that group are limited 7.

Hepatic Impairment

Patients with Child-Pugh class A and B hepatic impairment showed no meaningful change in inclisiran exposure versus normal hepatic function 7. Child-Pugh class C (severe) hepatic impairment has not been studied, and use in that group requires individual clinical judgment.

Elderly Patients

No dose adjustment is required for age alone. In ORION-10, patients aged 65 years and older (37% of the cohort) showed LDL-C reductions consistent with the overall population, with no excess adverse events 13.

Pediatric Patients

Inclisiran has not been approved for any pediatric indication as of January 2025. Trials in children with HoFH and HeFH are underway but no data have been published 24.

Regulatory History and Pipeline

The FDA granted inclisiran approval on December 22, 2021, based on the ORION-9, -10, and -11 data package 7. The European Medicines Agency had approved the drug earlier in December 2020 25. In the United Kingdom, NICE initially declined to recommend inclisiran on cost-effectiveness grounds in 2021 but reversed this position in 2022 following a revised commercial agreement 26.

Emerging siRNA Targets in Lipid Metabolism

Several second-generation siRNA lipid therapeutics are in active development:

• Zilebesiran (Alnylam/Roche): targets hepatic angiotensinogen mRNA for blood pressure reduction; not a lipid agent but uses identical GalNAc-siRNA technology, confirming platform scalability 27.
• Zodasiran (previously ARO-ANG3): targets angiopoietin-like protein 3 (ANGPTL3) mRNA and reduces triglycerides by approximately 53% and LDL-C by approximately 23% in phase 2 28.
• Plozasiran (previously ARO-APOC3): targets APOC3 mRNA; phase 3 trials underway for hypertriglyceridemia and familial chylomicronemia syndrome 29.

These pipeline agents extend the siRNA lipid class well beyond PCSK9, with different target populations and lipid fractions 28.

Adherence, Adherence Advantages, and Real-World Considerations

Adherence to lipid-lowering therapy is notoriously poor. A 2019 analysis of 347,104 statin users found that only 44% achieved medication possession ratios above 80% at 2 years 30. Twice-yearly dosing substantially reduces the number of adherence decision points compared with daily oral agents or biweekly injectables. Published modeling based on ORION-10 LDL-C data suggests that the time-averaged LDL-C reduction achieved with inclisiran's dosing schedule is comparable to what a perfectly adherent patient on a PCSK9 monoclonal antibody would achieve, but is much more resilient to missed doses 31.

The in-office administration requirement in the United States, while operationally burdensome, creates an opportunity for confirmed delivery that self-injection regimens cannot guarantee. Practices managing high-risk cardiovascular patients may find the structured 6-month visit rhythm aligns with standard lipid monitoring intervals 9.

Cost remains a barrier. The list price of inclisiran in the United States is approximately $3,500 per injection, or $6,000, $7,000 annually 32. Patient assistance programs and payer-specific prior authorization pathways apply in most commercial and Medicare Part B plans. The 2022 AHA/ACC guideline specifically notes that a shared decision-making conversation about cost is appropriate before initiating any PCSK9-targeting agent 9.

The guideline states: "For patients with ASCVD whose LDL-C level remains >70 mg/dL (or non-HDL-C level remains >100 mg/dL) on maximally tolerated statin therapy and ezetimibe, it is reasonable to add a PCSK9 inhibitor" (Class IIa, Level of Evidence A) 9.

Key Pharmacist Considerations

Pharmacists dispensing or preparing inclisiran should be aware of the following points:

• The drug is stored at room temperature (up to 30°C / 86°F) and should not be frozen 7.
• Each prefilled syringe is single-use. Partial use is not permitted 7.
• In the United States, inclisiran is classified as a physician-administered drug under most payer systems and bills under the medical benefit rather than the pharmacy benefit, which affects prior authorization workflows 33.
• Refrigerated storage is acceptable during transport (2 to 8°C), but the drug should be allowed to reach room temperature before injection to reduce injection-site discomfort 7.
• Because inclisiran is not a CYP substrate, medication reconciliation focuses on the patient's lipid panel response rather than pharmacokinetic interactions 6.